文献速递心脑血管急症

短暂性脑缺血发作或轻型缺血性卒中后5年卒中风险

Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke.
PubMed 文献 · N Engl J Med · 2018-05-16
一句话结论TIA或轻型卒中后5年复合心血管事件累积发生率12.9%,其中50.1%发生在第2至第5年,卒中累积发生率9.5%。

该研究为21个国家TIA门诊注册研究的5年随访,纳入3847例7天内发生TIA或轻型缺血性卒中的患者。主要终点为卒中、急性冠脉综合征或心血管死亡复合终点,5年累积发生率12.9%(95%CI 11.8-14.1),其中235例(50.1%)发生在第2至第5年。5年卒中累积发生率9.5%(95%CI 8.5-10.5),43.2%的卒中发生在第2至第5年。同侧大动脉粥样硬化、心源性栓塞及基线ABCD2评分≥4分与后续卒中风险增加相关。

要点

  • TIA或轻型卒中后5年复合心血管事件(卒中、急性冠脉综合征或心血管死亡)累积发生率12.9%(95%CI 11.8-14.1)。
  • 5年卒中累积发生率9.5%(95%CI 8.5-10.5),其中43.2%(149/345)发生在第2至第5年。
  • 复合终点事件中50.1%(235/469)发生在第2至第5年,提示长期二级预防不能松懈。
  • 同侧大动脉粥样硬化、心源性栓塞、基线ABCD2评分≥4分(范围0-7分)各自与后续卒中风险增加相关。
  • 5年全因死亡10.6%、心血管死亡2.7%、颅内出血1.1%、大出血1.5%。

适用人群与场景

  • 2009年至2011年入组、在入组前7天内发生TIA或轻型缺血性卒中的患者,来自21个国家TIA门诊注册研究。
  • 5年随访分析纳入61个参与1年结局研究的中心中42个5年随访数据超过50%的中心,共3847例患者。

诊断标准与关键阈值

  • 基线ABCD2评分用于卒中风险评估,范围0至7分,评分越高风险越大;评分≥4分与后续卒中风险增加相关。

研究设计与关键结果

  • 研究类型为TIA门诊注册研究的5年随访分析,纳入3847例患者,来自42个中心,每中心5年随访数据中位百分比92.3%(四分位距83.4至97.8)。
  • 主要终点为卒中、急性冠脉综合征或心血管死亡的复合终点(以先发生者为准),469例发生主要终点,估计累积发生率12.9%(95%CI 11.8至14.1),其中235例(50.1%)发生在第2至第5年。
  • 5年时345例发生卒中,估计累积发生率9.5%(95%CI 8.5至10.5),其中149例(43.2%)发生在第2至第5年。
  • 5年时全因死亡、心血管死亡、颅内出血、大出血的发生率分别为10.6%、2.7%、1.1%、1.5%。
  • 多变量分析中,同侧大动脉粥样硬化、心源性栓塞、基线ABCD2评分≥4分各自与后续卒中风险增加相关。
  • 心血管事件(包括卒中)发生率第1年为6.4%,第2至第5年为6.4%。

证据类型、等级与局限

  • 证据类型为注册研究的随访分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者报告TIA或轻型卒中后第2至第5年仍有约一半的复合心血管事件和43.2%的卒中发生,提示随访中需关注长期风险。
  • 作者报告同侧大动脉粥样硬化、心源性栓塞、基线ABCD2评分≥4分与后续卒中风险增加相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: After a transient ischemic attack (TIA) or minor stroke, the long-term risk of stroke and other vascular events is not well known. In this follow-up to a report on 1-year outcomes from a registry of TIA clinics in 21 countries that enrolled 4789 patients with a TIA or minor ischemic stroke from 2009 through 2011, we examined the 5-year risk of stroke and vascular events.

METHODS: We evaluated patients who had had a TIA or minor stroke within 7 days before enrollment in the registry. Among 61 sites that participated in the 1-year outcome study, we selected 42 sites that had follow-up data on more than 50% of their enrolled patients at 5 years. The primary outcome was a composite of stroke, acute coronary syndrome, or death from cardiovascular causes (whichever occurred first), with an emphasis on events that occurred in the second through fifth years. In calculating the cumulative incidence of the primary outcome and secondary outcomes (except death from any cause), we treated death as a competing risk.

RESULTS: A total of 3847 patients were included in the 5-year follow-up study; the median percentage of patients with 5-year follow-up data per center was 92.3% (interquartile range, 83.4 to 97.8). The composite primary outcome occurred in 469 patients (estimated cumulative rate, 12.9%; 95% confidence interval [CI], 11.8 to 14.1), with 235 events (50.1%) occurring in the second through fifth years. At 5 years, strokes had occurred in 345 patients (estimated cumulative rate, 9.5%; 95% CI, 8.5 to 10.5), with 149 of these patients (43.2%) having had a stroke during the second through fifth years. Rates of death from any cause, death from cardiovascular causes, intracranial hemorrhage, and major bleeding were 10.6%, 2.7%, 1.1%, and 1.5%, respectively, at 5 years. In multivariable analyses, ipsilateral large-artery atherosclerosis, cardioembolism, and a baseline ABCD2 score for the risk of stroke (range, 0 to 7, with higher scores indicating greater risk) of 4 or more were each associated with an increased risk of subsequent stroke.

CONCLUSIONS: In a follow-up to a 1-year study involving patients who had a TIA or minor stroke, the rate of cardiovascular events including stroke in a selected cohort was 6.4% in the first year and 6.4% in the second through fifth years. (Funded by AstraZeneca and others.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Amarenco P, Lavallée PC, Monteiro Tavares L, et al. Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. N Engl J Med. 2018. PMID: 29766771. doi:10.1056/NEJMoa1802712

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。